These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26284586)

  • 1. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
    Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
    Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
    Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
    Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
    Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
    J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
    Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
    Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
    Wei WJ; Shen CT; Song HJ; Qiu ZL; Luo QY
    Oncol Rep; 2016 Sep; 36(3):1576-84. PubMed ID: 27432558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Endocrinol Invest; 2013 Dec; 36(11):1099-104. PubMed ID: 24084189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
    Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
    Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
    Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.
    Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK
    BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
    Liu D; Xing J; Trink B; Xing M
    Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
    J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy sustains mitochondrial respiration and determines resistance to BRAF
    Díaz-Gago S; Vicente-Gutiérrez J; Ruiz-Rodríguez JM; Calafell J; Álvarez-Álvarez A; Lasa M; Chiloeches A; Baquero P
    Autophagy; 2024 Jun; 20(6):1383-1397. PubMed ID: 38436206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.